Key result
Embolization of hypervascular renal tumors with Ta-OCE achieved 100% technical success and a significant mean tumor diameter reduction of 1.03 cm without significant decline in renal function.
Why the study?
To evaluate the efficacy and safety of renal artery embolization in hypervascular renal tumors using Tantalum-Loaded Obsidio Conformable Embolic.
Does renal artery embolization with Ta-OCE reduce tumor size and preserve renal function in patients with hypervascular renal tumors?
Observational (n=10)
No
Does renal artery embolization with Ta-OCE reduce tumor size and preserve renal function in patients with hypervascular renal tumors?
Embolization of hypervascular renal tumors with Ta-OCE is technically feasible, safe, and effectively reduces tumor size without significantly impairing short-term renal function.
This is the authors' abstract. We don't add key points for this paper.
Purpose To evaluate the efficacy and safety of renal artery embolization (RAE) in hypervascular renal tumors using Tantalum-Loaded Obsidio™ Conformable Embolic (Ta-OCE). Methods A single-center institutional review board (IRB) approved retrospective analysis of consecutive patients with benign and malignant hypervascular renal tumors treated with Ta-OCE between May 2023 and June 2024 was performed. Specific clinical data on tumor size reduction, renal function preservation, bleeding, and complications were collected. Follow-up imaging was conducted using MRI or CT scans. Adverse events were evaluated according to the Common Toxicity Criteria for Adverse Events (v.5). Student’s t-test was used to compare continuous variables. Results Overall, N = 10 patients (mean age 64.1 + 14.9 (SD) years, 46% female) were included; 5 patients with renal cell carcinoma (RCC) and 5 patients with angiomyolipoma (AML). Technical success was achieved in all 10 patients. There was a significant reduction in tumor diameter of 1.03 cm following embolization ( p = 0.0009). There was no significant change in renal function post-RAE at 1 month, GFR pre-(72.8 ± 23.5 mL/min/1.73 m 2 , GFR post 63 ± 24.7 mL/min/1.73 m 2 , with a mean change in GFR (%) of − 13.5 ± 11.2%. ( p = 0.116). Additionally, no significant bleeding requiring further intervention was experienced. One patient experienced a Grade 1 adverse effect due to an underlying heart condition. Conclusion Embolization of hypervascular renal tumors with Ta-OCE appears to be safe and effective. Prospective, ideally multicenter studies are needed to further clarify the ideal scenarios for the use of Ta-OCE in hypervascular renal tumors.
Answers are grounded in this paper and cite their sources.
Supports further investigation of Ta-OCE for hypervascular renal tumors; hypothesis-generating and should not yet alter practice.
No takes yet. Share an insight, caveat, or question.
Gad et al. (2025) conducted an observational in Hypervascular renal tumors (renal cell carcinoma and angiomyolipoma) (n=10). Tantalum-Loaded Obsidio Conformable Embolic (Ta-OCE) was evaluated on Tumor diameter reduction (1.03 cm reduction, p=0.0009). Embolization of hypervascular renal tumors with Ta-OCE achieved 100% technical success and a significant mean tumor diameter reduction of 1.03 cm without significant decline in renal function.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: